Lu, Shun
Shanghai Jiao Tong University · Shanghai Chest Hospital
4 papers on CoChatORCID 0000-0001-8833-7262
Most cited papers
- Verified
Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Reck, M., Ciuleanu, T.-E., Dols, M. C., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2020) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 153
- Verified
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Spicer, J., Wang, C., Tanaka, F., Saylors, G. B., Chen, K.-N., Liberman, M., Vokes, E. E., Girard, N., Lu, S., Provencio, M., et al. (2021) · Journal of Clinical Oncology
Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 139
- Verified
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., et al. (2025) · New England Journal of Medicine
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 70
- Verified
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 65
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free